Vildagliptin was generally shown to have a beneficial or neutral effect on lipid parameters; however, one study reported a small decrease in HDL cholesterol levels, ...

Treatment with vildagliptin for 12 weeks produced the same improvements in individuals with impaired glucose tolerance as it did in those with type 2 diabetes. The beneficial effects of ...

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control.

A recent study has found that a single dose of the DPP-IV inhibitor vildagliptin caused a significant suppression of endogenous glucose production in patients with type 2 diabetes.

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control.

Combination vildagliptin and metformin can improve glycemic control in Japanese patients with type 2 diabetes mellitus (T2DM) without inducing tolerability issues or hypoglycemia, a new study ...

Wu T, Trahair LG, Little TJ, et al. Effects of Vildagliptin and Metformin on blood pressure and heart rate responses to small intestinal glucose in type 2 diabetes. Diabetes Care . 3 March 2017 ...

(HealthDay)—The dipeptidyl peptidase-4 (DPP-4) inhibitors vildagliptin and sitagliptin have similar effects on incretin hormone secretion, according to a study published online June 14 in ...

If vildagliptin is approved for marketing, it will add to the available treatment options for diabetes and will provide patients and health care providers with another noninjectable therapy option.

Vildagliptin (trade name Galvus or Jalra) has been approved since September 2007 for adults with type 2 diabetes mellitus in whom diet and exercise do not provide adequate glycaemic control. The ...